Shield Therapeutics plc
Shield Therapeutics plc, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on developing innovative therapies for iron deficiency and related conditions. Founded in 2013, the company has made significant strides in the industry, particularly with its flagship product, Accrufer® (ferric maltol), which offers a unique oral treatment option for patients with iron deficiency anaemia. With a strong presence in both the UK and the US markets, Shield Therapeutics is committed to addressing unmet medical needs through its advanced formulations. The company has achieved notable milestones, including successful regulatory approvals and partnerships that enhance its market position. By prioritising patient-centric solutions, Shield Therapeutics continues to set itself apart in the biopharmaceutical landscape, driving advancements in iron therapy.
DitchCarbon Score
How does Shield Therapeutics plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shield Therapeutics plc's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shield Therapeutics plc's reported carbon emissions
Shield Therapeutics plc, headquartered in Great Britain, currently does not report any carbon emissions data, as indicated by the absence of specific figures in their latest emissions report. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Shield Therapeutics may not have established formal commitments to reduce carbon emissions or engage in climate initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, it will be important for Shield Therapeutics to consider developing and communicating their climate commitments in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shield Therapeutics plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
